Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia. (February 2022)

• Record Type: Journal Article
• Authors: Rekhi, Gurpreet; Tay, Jenny; Lee, Jimmy
• Is Part Of: Journal of psychopharmacology. Volume 36:Number 2(2022)
• Page Start: 183
• Page End: 190
• Publication Date: 2022-02
• Subjects: Drug-induced Parkinsonism -- tardive dyskinesia -- health-related quality of life -- EQ-5D-5L utility scores; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/02698811211055812
• Languages: English
• ISSNs: 0269-8811

Abstract

Background: Both drug-induced Parkinsonism (DIP) and tardive dyskinesia (TD) have been shown to be associated with lower health-related quality of life (HRQOL) in schizophrenia, but few studies have examined their relative impact. Aims: This study aimed to examine and compare the association of DIP and TD with HRQOL in schizophrenia. Methods: In total, 903 patients with schizophrenia were assessed on the Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), and Abnormal Involuntary Movement Scale (AIMS). EuroQoL five-dimensional (EQ-5D-5L) utility scores were derived from PANSS scores via a previously validated algorithm and used as a measure of HRQOL. Results: In total, 160 (17.7%) participants had only DIP, 119 (13.2%) had only TD, and 123 (13.6%) had both DIP and TD. HRQOL was lowest for participants with both DIP and TD, followed by only DIP group, only TD group, and highest in the group with neither condition. HRQOL scores differed significantly between the four groups, F (3, 892) = 13.724, p < 0.001, η p 2 = 0.044). HRQOL of participants having only DIP or both DIP and TD was significantly lower than those having neither condition. There was no significant interaction between the presence of DIP and TD on the association with HRQOL. Conclusions: DIP was the main antipsychotic-induced movement disorder associated with a poorer HRQOL in patients with schizophrenia. Therefore, clinicians should focus on prevention, detection, and effective management of DIP to optimize HRQOL in patients with schizophrenia.